PrimeVigilance

PrimeVigilance provides end-to-end pharmacovigilance and medical information services for pharmaceutical, biotechnology, and medical device companies globally. It supports clients from clinical development through post-marketing with expertise in safety systems, benefit-risk management, case processing, GVP audits, inspection preparedness, and regulatory compliance[1][2][3][4].

The company manages global pharmacovigilance systems for over 200 clients across more than 100 countries[5].

It has recently expanded its portfolio in generics and biosimilars through the acquisition of Panacea[5].

No clinical results or pipeline as it does not develop drugs.